408 related articles for article (PubMed ID: 30282317)
1. Copper radiopharmaceuticals for theranostic applications.
Ahmedova A; Todorov B; Burdzhiev N; Goze C
Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.
Boschi A; Martini P; Janevik-Ivanovska E; Duatti A
Drug Discov Today; 2018 Aug; 23(8):1489-1501. PubMed ID: 29635027
[TBL] [Abstract][Full Text] [Related]
4. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.
Cai Z; Anderson CJ
J Labelled Comp Radiopharm; 2014 Apr; 57(4):224-30. PubMed ID: 24347474
[TBL] [Abstract][Full Text] [Related]
5. Copper-64: a real theranostic agent.
Gutfilen B; Souza SA; Valentini G
Drug Des Devel Ther; 2018; 12():3235-3245. PubMed ID: 30323557
[TBL] [Abstract][Full Text] [Related]
6. The development of copper radiopharmaceuticals for imaging and therapy.
Shokeen M; Wadas TJ
Med Chem; 2011 Sep; 7(5):413-29. PubMed ID: 21711219
[TBL] [Abstract][Full Text] [Related]
7. Copper radionuclides and radiopharmaceuticals in nuclear medicine.
Blower PJ; Lewis JS; Zweit J
Nucl Med Biol; 1996 Nov; 23(8):957-80. PubMed ID: 9004284
[TBL] [Abstract][Full Text] [Related]
8. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.
Paterson BM; Donnelly PS
Chem Soc Rev; 2011 May; 40(5):3005-18. PubMed ID: 21409228
[TBL] [Abstract][Full Text] [Related]
9. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
Notni J; Wester HJ
J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
[TBL] [Abstract][Full Text] [Related]
10. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
11. IAEA contribution to the development of 64Cu radiopharmaceuticals for theranostic applications.
Jalilian AR; Osso JA; Vera-Araujo J; Kumar V; Harris MJ; Gutfilen B; Guérin B; Li H; Zhuravlev F; Chakravarty R; Alirezapour B; Ávila-Rodríguez MA; Khan IU; Aljammaz I; Assaad T; Luurtsema G; Smith J; Duatti A
Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):338-345. PubMed ID: 33026211
[TBL] [Abstract][Full Text] [Related]
12. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
[TBL] [Abstract][Full Text] [Related]
13. Cross-Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications.
Rosecker V; Denk C; Maurer M; Wilkovitsch M; Mairinger S; Wanek T; Mikula H
Chembiochem; 2019 Jun; 20(12):1530-1535. PubMed ID: 30742739
[TBL] [Abstract][Full Text] [Related]
14. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
Morgan KA; Rudd SE; Noor A; Donnelly PS
Chem Rev; 2023 Oct; 123(20):12004-12035. PubMed ID: 37796539
[TBL] [Abstract][Full Text] [Related]
15. Alternative routes for
Dellepiane G; Casolaro P; Mateu I; Scampoli P; Braccini S
Appl Radiat Isot; 2023 Jan; 191():110518. PubMed ID: 36327610
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles for SPECT and PET Imaging: Towards Personalized Medicine and Theranostics.
Polyak A; Ross TL
Curr Med Chem; 2018; 25(34):4328-4353. PubMed ID: 28875837
[TBL] [Abstract][Full Text] [Related]
17. An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions.
Farzin L; Sheibani S; Moassesi ME; Shamsipur M
J Biomed Mater Res A; 2019 Jan; 107(1):251-285. PubMed ID: 30358098
[TBL] [Abstract][Full Text] [Related]
18. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases.
Dyer MR; Jing Z; Duncan K; Godbe J; Shokeen M
Nucl Med Biol; 2024; 130-131():108879. PubMed ID: 38340369
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to medical radioisotope production using inverse kinematics: A successful production test of the theranostic radionuclide
Souliotis GA; Rodrigues MRD; Wang K; Iacob VE; Nica N; Roeder B; Tabacaru G; Yu M; Zanotti-Fregonara P; Bonasera A
Appl Radiat Isot; 2019 Jul; 149():89-95. PubMed ID: 31035108
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in copper radiopharmaceuticals.
Hao G; Singh AN; Oz OK; Sun X
Curr Radiopharm; 2011 Apr; 4(2):109-21. PubMed ID: 22191650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
